TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03672214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without placement of indwelling catheter
Description: No placement of indwelling catheter prior to Caesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: With placement of indwelling catheter
Description: Placement of indwelling catheter prior to Caesarean section
Study: NCT02922192

Intervention type: DRUG
Intervention: TNF-α antagonists, non-TNFs, DMARD non-biologics
Description: Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.

Intervention type: DRUG
Intervention: TNF-α antagonists, non-TNFs, DMARD non-biologics
Description: Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
Study: NCT03910621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: capsule, oral use
Study: NCT04632017

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized cardiotocography
Description: To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized cardiotocography
Description: To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing
Study: NCT02922192

Intervention type: DRUG
Intervention: TNF-α antagonists, non-TNFs, DMARD non-biologics
Description: Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
Study: NCT00022152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study: NCT01085526

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alutard phleum pratense subcutaneous immunotherapy
Description: standard regimen of SCIT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alutard phleum pratense subcutaneous immunotherapy
Description: standard regimen of SCIT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alutard phl prat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alutard phl prat
Study: NCT02136225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Means restriction counseling
Description: Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Means restriction counseling
Description: Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
Study: NCT04068454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality device
Description: Functional exercises will be done by virtual reality group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EBM rehabilitation exercises
Description: scapular exercises will be done
Study: NCT03693495

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ellume·lab Group A Streptococcus Test
Description: ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bacterial Culture
Description: Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polymerase Chain Reaction (PCR)
Description: Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
Study: NCT05379699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOR-BSST© eLearning Training
Description: An online self-directed training program for TOR-BSST© dysphagia screeners.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOR-BSST© eLearning Training
Description: An online self-directed training program for TOR-BSST© dysphagia screeners.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard TOR-BSST© Training
Description: Standard 4-hour in-person TOR-BSST© screener training conducted by a Speech-Language Pathologist.
Study: NCT00928343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0187
Description: Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching subcutaneous or oral placebo
Study: NCT04734158

Intervention type: OTHER
Intervention: corneal imaging
Description: corneal imaging using AS-OCT

Intervention type: OTHER
Intervention: corneal imaging
Description: corneal imaging using AS-OCT

Intervention type: OTHER
Intervention: corneal imaging
Description: corneal imaging using AS-OCT
Study: NCT03384875

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CytoSorb
Description: To evaluate the safety and performance of the CytoSorb® device to decrease the incidence or severity of acute kidney injury (AKI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: To evaluate the safety and performance of the CytoSorb® device to decrease the incidence or severity of acute kidney injury (AKI)
Study: NCT04459416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be scheduled to cover the period of high symptom burden. Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. Electrical stimulation (e-acupuncture) may be applied to the ST36 and SP6 points when appropriate as per standard acupuncture practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid
Description: All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid
Description: All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessments
Description: Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessments
Description: Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.
Study: NCT01619917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Vascular Laser
Description: laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Vascular Laser
Description: laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
Study: NCT02275507

Intervention type: DEVICE
Intervention: Masimo Rainbow Sensor
Description: Non-Invasive Hemoglobin Measurement
Study: NCT02495285

Intervention type: DRUG
Intervention: Gelofusine 4%

Intervention type: DRUG
Intervention: Gelaspan 4%
Study: NCT01826630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLn BodyWash
Description: Comparing two washes to determine change in bacterial load.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil Daily Facial Cleanser
Description: Comparing two washes to determine change in bacterial load.
Study: NCT04591002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib 80 MG
Description: Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. Osimertinib will be administered orally as one 80 mg tablet once a day (1 cycle is 28 days). Cycles are repeated until disease progression, unacceptable toxicity, or until 1 year after the initiation of osimertinib administration.
Study: NCT01826604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexis O C-Section Retractor
Description: The Alexis O C-section retractor will be used.
Study: NCT03247829

Intervention type: DEVICE
Intervention: Hemodynamic management using CardioMEMS HF System
Description: Using the CardioMEMS HF System, clinicians will treat to target PA pressure ranges

Intervention type: DEVICE
Intervention: Hemodynamic management using CardioMEMS HF System
Description: Using the CardioMEMS HF System, clinicians will treat to target PA pressure ranges
Study: NCT02022709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvoxamine
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention
Description: 8 exposure and response prevention (ERP) sessions,once a week
Study: NCT02659605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping above the perineum
Description: After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping below the perineum
Description: The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
Study: NCT04782986

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pan-intestinal capsule endoscopy
Description: Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pan-intestinal capsule endoscopy
Description: Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation
Study: NCT02710539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perindopril, indapamide , amlodipine
Description: Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tripliam (perindopril, indapamide, amlodipine)
Description: Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
Study: NCT03174327

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hepatic Transplantation
Description: Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.
Study: NCT02868853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo App
Description: Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet App
Description: Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Podcasts
Description: Listen to 2 podcasts per week about healthy eating and exercise.
Study: NCT04184115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPI-386 Nasal Gel
Description: 1.5 mg reservoir of scopolamine to be delivered over a 72-hour period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPI-386 Nasal Gel
Description: 1.5 mg reservoir of scopolamine to be delivered over a 72-hour period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo Nasal Gel and placebo patch
Study: NCT02868853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcasts
Description: Listen to 2 podcasts per week about healthy eating and exercise.
Study: NCT01889394

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: secondary wound healing
Description: secondary wound healing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary wound closure using a limberg flap
Description: primary wound closure using a limberg flap
Study: NCT01826604

Intervention type: OTHER
Group type: OTHER
Intervention: Control- Conventional retractors
Description: Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
Study: NCT04184115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Nasal Gel and placebo patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Placebo Nasal Gel and placebo patch
Study: NCT03795818

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal Psychotherapy for Adolescents
Description: IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
Study: NCT01836289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Cyclophosphamide
Study: NCT03644719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral skills training
Description: A brief cognitive behavioral skills training was applied to teach ketamine abusers about stimulus control, refusal skills, communication skills, decisional balance, and infectious diseases prevention.
Study: NCT01306396

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: dietary intervention mainly focusing on fructose reduction
Description: Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
Study: NCT01587820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatin
Description: 150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous cisplatin
Description: 100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
Study: NCT01402414

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Bath-PUVA
Description: Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB plus salt water baths
Description: First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
Study: NCT01994447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Student Enrollment
Description: The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
Study: NCT03130257

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Blood Pressure Measurement
Description: Participants will be asked to check their blood pressure once within the subsequent three weeks.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Home Blood Pressure Measurement
Description: Participants will receive a validated upper-arm home blood pressure monitor and asked to two measurements in the morning and two in the evening for at least 5 days over three weeks.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Kiosk Blood Pressure Measurement
Description: Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)
Description: Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)
Description: Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)
Description: Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.
Study: NCT02255539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geelong Prototype Mask
Description: A nasal pillows prototype mask to be trialled with a PAP therapy device for a period of 6 weeks. Participants will wear the mask in place of their current mask for the duration of the trial.
Study: NCT00212836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: 5-10 mg sublingually twice daily for 26 weeks
Study: NCT02478996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based exercise program
Description: Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
Study: NCT03148132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: 0.5mg/0.02 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Ophthalmic
Description: 0.25mg/0.025 mL
Study: NCT00899574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease.
Study: NCT04303819

Intervention type: DRUG
Intervention: Exenatide treatment
Description: 12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.
Study: NCT04213079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: re-adaptation of the vestibulo-ocular reflex
Description: The VOR will be readapted by activating velocity storage with full-field optokinetic motion at 5°/s in a set direction while the head is oscillated with a set frequency and direction. The readaptation training will be conducted in repeated modules, each lasting for 1-5 min. The expected duration of daily sessions varies from 30 to 90 min. A day's session will be terminated if patient no longer feel symptoms of MdDS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habituation of velocity storage of the vestibulo-ocular reflex
Description: The central (velocity storage) time constant will be reduced by inducing cancellation of two velocity storage-mediated responses: OKN and the VOR. Sinusoidal rotation at 0.017 Hz (1 revolution/min) in darkness advances the slow phase eye velocity of the VOR by 32º. In contrast, the OKN at this frequency has no phase advancement. Thus, to counteract the VOR by OKN, the optokinetic stimulus should be set to 32º phase advance the out of phased head rotation stimulus. Since the conflict stimulus is expected to be overwhelming to patients at higher chair velocities, subjects will be first trained with a 10°/s stimulus. In a previous study, no complaints were reported when subjects were tested at such low velocities. Preliminary testing show signs of symptom improvement when the peak velocity reached 30°/s to 40°/s.